Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 5/20 | 0.56 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.50 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | BCR | P11274 | 1/20 | 0.46 |
| ▸ | FBP1 | P09467 | 2/20 | 0.46 |
| ▸ | VCP | P55072 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3499948 | 1.00 | NFE2L2 (0.56) | NFE2L2VCAM1LMNASMN1; SMN2MEN1 | |
| SCHEMBL22040900 | 0.81 | VCAM1 (0.54) | VCAM1LMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL1903144 | 0.81 | PLA2G4A (0.59) | VCAM1LMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL31697463 | 0.81 | PLA2G4A (0.59) | VCAM1LMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL15709537 | 0.81 | PLA2G4A (0.59) | VCAM1LMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL1903142 | 0.81 | PLA2G4A (0.59) | VCAM1LMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL14880649 | 0.80 | ALDH1A1 (0.60) | VCAM1LMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL23891778 | 0.80 | VCAM1 (0.53) | VCAM1LMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL4309326 | 0.80 | VCAM1 (0.65) | NFE2L2VCAM1LMNAMEN1KMT2A | |
| SCHEMBL811420 | 0.80 | NFE2L2 (0.56) | NFE2L2LMNASMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-27 | — | — | US | disclosed |
| EP-1849465-A1 | AGENT FOR CONTROLLING FUNCTION OF GPR34 RECEPTOR | Takeda Pharmaceutical Company Limited (JP) | 2007-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | GPR34, GPR4, GPR6 | NFE2L2 2132/4885VCAM1 2790/4885LMNA 4645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.